ClinicalTrials.Veeva

Menu

Healing Potentiality of Trypsin and Alpha Chemo Trypsin in Mandibular Molars With Chronic Apical Abscess

A

Ain Shams University

Status and phase

Not yet enrolling
Phase 4

Conditions

Mandibular Abscess

Treatments

Drug: Alphintern® , tablet, Amoun, Egypt

Study type

Interventional

Funder types

Other

Identifiers

NCT06164509
AinShamsUNII

Details and patient eligibility

About

assessment of healing potentiality of peri apical lesions using different doses of trypsin and alpha chemo trypsin in mandibular molars with chronic apical abscess

Full description

Owing to anti-inflammatory, anti-oedematous, fibrinolytic, anti-infective, and analgesic effects, trypsin:

chymotrypsin oral combination has emerged as a promising treatment of mandibular molars with chronic apical abscess. Trypsin chymotrypsin combination always showed a significant reduction in swelling and pain postoperatively.

Study procedures:

  1. According to inclusion and exclusion criteria; patients will be subjected to complete history taking, general and local "dental" examinations.
  2. Important dental symptoms will be assessed include bleeding, pain, malocclusion, new growths, numbness or paresthesias, and chewing problems.
  3. General information will be reported including use of alcohol or tobacco and systemic symptoms, such as fever and weight loss.
  4. A thorough inspection with good illumination, a tongue blade, gloves, and a gauze pad will be performed.
  5. Complete or partial dentures will be removed so that underlying soft tissues can be seen.
  6. A head-mounted light will be used. However, because the light cannot be precisely aligned on the axis of vision, it is difficult to avoid shadowing in narrow areas.
  7. Better illumination results will be performed with a head-mounted convex mirror.
  8. The temporomandibular joint (TMJ) will be assessed by looking for jaw deviation on opening and by palpating the head of the condyle anterior to the external auditory meatus.
  9. Examiner then place his little fingers into the external ear canals with the pads of the fingertips lightly pushing anteriorly while patients repeatedly open widely and then close.
  10. Preoperative preapical X-ray and CBCT will be done.
  11. Cases will be randomly divided into 3 groups; Group A will receive (Alphintern®, tablet, Amoun, Egypt), Group B will receive (Limitless Allzyme Max®, tablet, Eva, Egypt) Group C will not receive medication
  12. Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.
  13. Randomization, allocation and concealment: It will be done using computer generated randomization sheet. Sealed opaque packages will be given to a third person (nurse) who will assign the packages to study groups. Each patient will be invited to pull out a package. According to the number inside package, cases will be allocated to either group A, B or C according to a computer- generated random list.
  14. Postoperative preapical X-ray will be done at the end of the root canal treatment.
  15. Patient will be recalled after three months for preapical X-ray assessment.
  16. After six months patient will be recalled for preapical X-ray and CBCT to be done.

Enrollment

45 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age: any age group.
  2. Both genders.
  3. Cases with mandibular molars with chronic apical abscess

Exclusion criteria

  1. Patients with significant comorbidities like uncontrolled diabetes mellitus, hypertension, hepatic or renal disorders.
  2. Immunocompromised patients.
  3. Patient with allergy from study medications.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

45 participants in 3 patient groups

Alphintern
Active Comparator group
Description:
Group A will receive (Alphintern® tablet, Amoun, Egypt),
Treatment:
Drug: Alphintern® , tablet, Amoun, Egypt
Alzyme Max
Active Comparator group
Description:
Group B will receive (Limitless Allzyme Max®, tablet, Eva, Egypt)
Treatment:
Drug: Alphintern® , tablet, Amoun, Egypt
Placebo
No Intervention group
Description:
Group C will not receive medication

Trial contacts and locations

1

Loading...

Central trial contact

Dr. Maram Obied, professor; Ghassan Salameh, Master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems